

## Liquidity providing agreement terminated

Amniotics AB (publ) has terminated its agreement with Lago Kapital regarding liquidity providing for the company's shares. The purpose of the liquidity providing was to promote the share's liquidity and reduce its volatility, thereby facilitating share trading. The company believes that the liquidity providing is no longer needed. The agreement expires on January 5, 2023.

### For more information please contact

---

Marcus Larsson  
CEO, Amniotics AB  
Phone: +46 (0) 763 0840 91  
Email: [ml@amniotics.com](mailto:ml@amniotics.com)

or  
Johnny Humaloja  
CFO, Amniotics AB  
Phone: +46 (0) 735 0668 56  
Email: [jh@amniotics.com](mailto:jh@amniotics.com)

### About Amniotics

---

Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University Hospital of Lund, the company is pioneering the harvesting and propagation of tissue specific neonatal quality mesenchymal stem cells (MSC). These stem cells have unique properties for applications in regenerative medicine. Amniotics has also an, by Läkemedelsverket (Swedish MPA), approved Good Manufacturing Practice (GMP) facility to produce Advanced Therapy Medicinal Products (ATMPs). With the GMP facilities operational since 2020, Amniotics is now in clinical phase with the leading drug candidate PulmoStem™. The company is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs.

Amniotics (publ) has its headquarter in Lund, Sweden.

The company is listed at Nasdaq First North Growth Market in Stockholm.  
Amniotics Certified Adviser at First North is Redeye AB, e-post: [certifiedadviser@redeye.se](mailto:certifiedadviser@redeye.se).  
Learn more at [www.amniotics.com](http://www.amniotics.com).

Press Release  
08 December 2022 07:45:00 CET



## Attachments

---

Liquidity providing agreement terminated